Usana Health Sciences/$USNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Usana Health Sciences
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Ticker
$USNA
Sector
Primary listing
NYSE
Industry
Personal Care Products
Headquarters
Employees
1,700
ISIN
US90328M1071
Website
USNA Metrics
BasicAdvanced
$580M
17.13
$1.82
0.64
-
Price and volume
Market cap
$580M
Beta
0.64
52-week high
$48.85
52-week low
$23.10
Average daily volume
156K
Financial strength
Current ratio
2.048
Quick ratio
1.307
Total debt to equity
3.939
Interest coverage (TTM)
89.57%
Profitability
EBITDA (TTM)
72.338
Gross margin (TTM)
80.53%
Net profit margin (TTM)
3.98%
Operating margin (TTM)
6.54%
Effective tax rate (TTM)
47.24%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
5.21%
Return on equity (TTM)
6.42%
Valuation
Price to earnings (TTM)
17.134
Price to revenue (TTM)
0.678
Price to book
1.12
Price to tangible book (TTM)
2.45
Price to free cash flow (TTM)
12.088
Free cash flow yield (TTM)
8.27%
Free cash flow per share (TTM)
257.53%
Growth
Revenue change (TTM)
-2.69%
Earnings per share change (TTM)
-43.40%
3-year revenue growth (CAGR)
-8.70%
10-year revenue growth (CAGR)
0.57%
3-year earnings per share growth (CAGR)
-30.60%
10-year earnings per share growth (CAGR)
-4.84%
What the Analysts think about USNA
Analyst ratings (Buy, Hold, Sell) for Usana Health Sciences stock.
Bulls say / Bears say
USANA Health Sciences reported a 9.5% year-over-year increase in revenue for Q1 2025, reaching $249.54 million, surpassing analyst expectations of $243.04 million. (TradingView News)
The company plans to launch over 20 new products in 2025 and projects a 29-42% revenue growth for its recently acquired Hiya Health, indicating a strong growth strategy. (Investing.com)
USANA ended 2024 with $182 million in cash reserves and aims to increase this by $50-$60 million in 2025, reflecting a solid financial position. (Investing.com)
Net earnings for Q1 2025 declined by 43% to $9.4 million from $16.5 million in the previous year, despite increased sales. (TipRanks)
The stock has experienced a significant decline, losing about 33.6% since the beginning of the year, underperforming the S&P 500's decline of 12.3%. (Finviz)
Insider selling activity, including the CEO selling 5,000 shares in March 2025, may raise concerns about internal confidence in the company's future performance. (American Banking and Market News)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
USNA Financial Performance
Revenues and expenses
USNA Earnings Performance
Company profitability
USNA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Usana Health Sciences stock?
Usana Health Sciences (USNA) has a market cap of $580M as of June 28, 2025.
What is the P/E ratio for Usana Health Sciences stock?
The price to earnings (P/E) ratio for Usana Health Sciences (USNA) stock is 17.13 as of June 28, 2025.
Does Usana Health Sciences stock pay dividends?
No, Usana Health Sciences (USNA) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Usana Health Sciences dividend payment date?
Usana Health Sciences (USNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Usana Health Sciences?
Usana Health Sciences (USNA) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.